Antisense molecules for targeted cancer therapy

Critical Reviews in Oncology/Hematology

Volumn 59, Issue 1, 2006, Pages 65-73

  Wacheck, V ^a   Zangemeister Wittke, U ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Antisense oligonucleotides; Apoptosis; Cell signaling; Clinical trials; RNA interference

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; CARBOPLATIN; CHOLESTEROL; CISPLATIN; CYCLODEXTRIN; CYTOTOXIC AGENT; DACARBAZINE; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; GEMCITABINE; GENE PRODUCT; ISIS 3521; LIPID; LIPOSOME; MACROGOL; OBLIMERSEN; OGX 11; PACLITAXEL; POLYMER; PROTAMINE; SHORT HAIRPIN RNA; SINGLE STRANDED DNA; SMALL INTERFERING RNA; TRANSFERRIN; UNCLASSIFIED DRUG; VIRUS VECTOR;

BREAST TUMOR; CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CARCINOGENESIS; CELL ACTIVATION; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COMPREHENSION; CYTOMEGALOVIRUS INFECTION; DISEASE COURSE; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG SAFETY; DRUG SPECIFICITY; EWING SARCOMA; EXPERIENCE; GENE DELIVERY SYSTEM; GENE TARGETING; GENE TECHNOLOGY; GENETIC TRANSCRIPTION; GLIOMA; HEAD AND NECK TUMOR; HUMAN; KIDNEY CANCER; LUNG NON SMALL CELL CANCER; MELANOMA; METASTASIS; MOLECULAR GENETICS; NONHUMAN; ONCOGENE; PROSTATE CANCER; REGULATOR GENE; RETINITIS; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; TARGET CELL; UNSPECIFIED SIDE EFFECT;

ANIMALS; HUMANS; NEOPLASMS; OLIGONUCLEOTIDES, ANTISENSE;

EID: 33745159389     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2005.10.004     Document Type: Review

References (49)

1. Paterson B.M., Roberts B.E., and Kuff E.L. Structural gene identification and mapping by DNA-mRNA hybrid-arrested cell-free translation. Proc Natl Acad Sci USA 74 (1977) 4370-4374
2. Stephenson M.L., and Zamecnik P.C. Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc Natl Acad Sci USA 75 (1978) 285-288
3. Couzin J. Breakthrough of the year. Small RNAs make big splash. Science 298 (2002) 2296-2297
4. Napoli C., Lemieux C., and Jorgensen R. Introduction of a chimeric chalcone synthase gene into petunia results in reversible co-suppression of homologous genes in trans. Plant Cell 2 (1990) 279-289
5. van der Krol A.R., Mur L.A., Beld M., Mol J.N., and Stuitje A.R. Flavonoid genes in petunia: addition of a limited number of gene copies may lead to a suppression of gene expression. Plant Cell 2 (1990) 291-299
6. Fire A., Xu S., Montgomery M.K., Kostas S.A., Driver S.E., and Mello C.C. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391 (1998) 806-811
7. Mello C.C., and Conte Jr. D. Revealing the world of RNA interference. Nature 431 (2004) 338-342
8. Gautschi O., Tschopp S., Olie R.A., et al. Activity of a novel bcl-2/bcl-xL-bispecific antisense oligonucleotide against tumors of diverse histologic origins. J Natl Cancer Inst 93 (2001) 463-471
9. Gleave M.E., and Monia B.P. Antisense therapy for cancer. Nat Rev Cancer 5 (2005) 468-479
10. Nesterova M., and Cho-Chung Y.S. Killing the messenger: antisense DNA and siRNA. Curr Drug Targets 5 (2004) 683-689
11. Jansen B., and Zangemeister-Wittke U. Antisense therapy for cancer-the time of truth. Lancet Oncol 3 (2002) 672-683
12. Opalinska J.B., and Gewirtz A.M. Nucleic acid therapeutics: basic principles and recent applications. Nat Rev Drug Discov 1 (2002) 503-514
13. Donis-Keller H. Site specific enzymatic cleavage of RNA. Nucleic Acids Res 7 (1979) 179-192
14. Stein D., Foster E., Huang S.B., Weller D., and Summerton J. A specificity comparison of four antisense types: morpholino, 2′-O-methyl RNA, DNA, and phosphorothioate DNA. Antisense Nucleic Acid Drug Dev 7 (1997) 151-157
15. Monia B.P., Lesnik E.A., Gonzalez C., et al. Evaluation of 2′-modified oligonucleotides containing 2′-deoxy gaps as antisense inhibitors of gene expression. J Biol Chem 268 (1993) 14514-14522
16. Orum H., and Wengel J. Locked nucleic acids: a promising molecular family for gene-function analysis and antisense drug development. Curr Opin Mol Ther 3 (2001) 239-243
17. Nielsen P.E. Antisense properties of peptide nucleic acid. Methods Enzymol 313 (2000) 156-164
18. Bernstein E., Caudy A.A., Hammond S.M., and Hannon G.J. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 409 (2001) 363-366
19. Elbashir S.M., Lendeckel W., and Tuschl T. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev 15 (2001) 188-200
20. Martinez J., and Tuschl T. RISC is a 5′ phosphomonoester-producing RNA endonuclease. Genes Dev 18 (2004) 975-980
21. Elbashir S.M., Harborth J., Lendeckel W., Yalcin A., Weber K., and Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411 (2001) 494-498
22. Tong A.W., Zhang Y.A., and Nemunaitis J. Small interfering RNA for experimental cancer therapy. Curr Opin Mol Ther 7 (2005) 114-124
23. Soutschek J., Akinc A., Bramlage B., et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432 (2004) 173-178
24. Yu J.Y., DeRuiter S.L., and Turner D.L. RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells. Proc Natl Acad Sci USA 99 (2002) 6047-6052
25. McCaffrey A.P., Meuse L., Pham T.T., Conklin D.S., Hannon G.J., and Kay M.A. RNA interference in adult mice. Nature 418 (2002) 38-39
26. Vanhecke D., and Janitz M. High-throughput gene silencing using cell arrays. Oncogene 23 (2004) 8353-8358
27. Wang L., Prakash R.K., Stein C.A., Koehn R.K., and Ruffner D.E. Progress in the delivery of therapeutic oligonucleotides: organ/cellular distribution and targeted delivery of oligonucleotides in vivo. Antisense Nucleic Acid Drug Dev 13 (2003) 169-189
28. Schnierle B.S., and Groner B. Retroviral targeted delivery. Gene Ther 3 (1996) 1069-1073
29. Morizono K., and Chen I.S. Targeted gene delivery by intravenous injection of retroviral vectors. Cell Cycle (2005) 4
30. Felgner P.L., Gadek T.R., Holm M., et al. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci USA 84 (1987) 7413-7417
31. Wagner E., Cotten M., Foisner R., and Birnstiel M.L. Transferrin-polycation-DNA complexes: the effect of polycations on the structure of the complex and DNA delivery to cells. Proc Natl Acad Sci USA 88 (1991) 4255-4259
32. Li X., Stuckert P., Bosch I., Marks J.D., and Marasco W.A. Single-chain antibody-mediated gene delivery into ErbB2-positive human breast cancer cells. Cancer Gene Ther 8 (2001) 555-565
33. Song E., Zhu P., Lee S.K., et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol 23 (2005) 709-717
34. Allen T.M., and Cullis P.R. Drug delivery systems: entering the mainstream. Science 303 (2004) 1818-1822
35. Michael S.I., and Curiel D.T. Strategies to achieve targeted gene delivery via the receptor-mediated endocytosis pathway. Gene Ther 1 (1994) 223-232
36. Allen T.M., Sapra P., and Moase E. Use of the post-insertion method for the formation of ligand-coupled liposomes. Cell Mol Biol Lett 7 (2002) 889-894
37. Hu S., Heidel J.D., Barlett D.W., Kohn D.B., Davis M.E., and Triche T.J. Systemic targeted EWS-FLI1 siRNA abrogates growth of metastases in a murine Ewing's tumor model. Proc Am Assoc Cancer Res (2005) 6104
38. Biroccio A., Leonetti C., and Zupi G. The future of antisense therapy: combination with anticancer treatments. Oncogene 22 (2003) 6579-6588
39. Karagiannis T.C., and El-Osta A. RNA interference and potential therapeutic applications of short interfering RNAs. Cancer Gene Ther (2005)
40. Hede K. Blocking cancer with RNA interference moves toward the clinic. J Natl Cancer Inst 97 (2005) 626-628
41. Kirkwood J.M., Bedikian A.Y., Millward M.J., et al. Long-term survival results of a randomized multinational phase 3 trial of dacarbazine (DTIC) with or without Bcl-2 antisense (oblimersen sodium) in patients (pts) with advanced malignant melanoma (MM). Proc Am Soc Clin Oncol 24 (2005) 7506
42. Lynch Jr. T.J., Raju R., Lind M., et al. Randomized phase III trial of chemotherapy and antisense oligonucleotide LY900003 (ISIS 3521) in patients with advanced NSCLC: initial report. Proc Am Soc Clin Oncol 22 (2003) 623
43. Jansen B., Wacheck V., Heere-Ress E., et al. Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet 356 (2000) 1728-1733
44. Millward M.J., Bedikian A.Y., Conry M., et al. Randomized multinational phase 3 trial of dacarbazine (DTIC) with or without Bcl-2 antisense (oblimersen sodium) in patients (pts) with advanced malignant melanoma (MM): analysis of long-term survival. Proc Am Soc Clin Oncol (2004) 7505
45. Tolcher A., Mooberry S.L., Southwell T., Mangold G., and Rowinsky E.K. Optimal oblimersen (G3139) sequence and schedule of administration when combined with docetaxel in the PC3 human prostate tumor model. Proc Am Assoc Cancer Res (2003) #2755
46. Agrawal S., and Kandimalla E.R. Role of toll-like receptors in antisense and siRNA [corrected]. Nat Biotechnol 22 (2004) 1533-1537
47. Jackson A.L., Bartz S.R., Schelter J., et al. Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol 21 (2003) 635-637
48. Chi K.N., Eisenhauer E., Fazli L., et al. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2′-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst 97 (2005) 1287-1296
49. Wacheck V. Strategies for designing clinical trials for oligonucleotide therapeutics. Drug Discov Today 9 (2004) 918-923